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Primary fibromyalgia (FM) (previously called fibrositis) is a
clinically recognizable nonarticular rheumatic condition char-
acterized by widespread pain and hyperalgesia, mainly locat-
ed at the muscular level, associated with morning stiffness,
diffuse aching and soreness, fatigue, and sleep disturbances
(nonrestorative sleep)1-3. Affective disturbances, particularly
high levels of anxiety, depression, and hypocondriasis, have
also been noted among some patients4,5. However, perhaps the
most salient feature of this syndrome is a predictable anatom-
ical pattern of tender-points elicited by manual palpation6. In
fact, the existence and number of such tender point sites con-
stitutes one of the major defining characteristics of FM and
helps differentiate this syndrome from other closely related
musculoskeletal pain conditions, such as myofascial pain syn-
dromes and articular diseases7. FM has a female prevalence
usually occurring in middle-aged women4. To date, the patho-
physiology of this syndrome is not completely elucidated.
Even though a significant amount of research has been under-
taken in this area, no unified hypothesis on its etiology has
emerged and no single hypothesized mechanism can com-
pletely explain the origin of FM8. The main hypotheses fall
into 4 categories: sleep disturbance9, muscular alterations10,
altered neurotransmission of pain11, and immunological fac-
tors10. Results from studies that suggested a possible patho-
logic basis for FM in muscle indicating the pain experienced
by patients as the result of abnormalities in muscle blood flow,
tissue hypoxia or energy metabolism defects are controver-
sial12. At present, the most widely accepted model for the
pathogenesis of this syndrome invokes central mechanisms
rather than pathologically painful muscles13,14. Low serotonin
levels and elevated substance P levels, mediators involved in
the modulation of pain perception and in the regulation of
sleep, were found in the cerebrospinal fluid15,16, but not in
muscles17 of patients with primary FM.
A characteristic feature of this syndrome, in contrast to
other chronic pain conditions, is a diffuse hypersensitivity to
pain. The pain threshold is regulated by equilibrium between
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ABSTRACT. Objective. The etiopathogenesis of fibromyalgia (FM), a syndrome characterized by widespread pain
and hyperalgesia, is still unknown. Since the involvement of Gi proteins in the modulation of pain per-
ception has been widely established, the aim of the present study was to determine whether an altered
functionality of the Gi proteins occurred in patients with FM.
Methods. Patients with FM and other painful diseases such as neuropathic pain, rheumatoid arthritis
(RA), and osteoarthritis, used as reference painful pathologies, were included in the study. The func-
tionality, evaluated as capability to inhibit forskolin-stimulated adenylyl cyclase activity, and the level
of expression of Gi proteins were investigated in peripheral blood lymphocytes.
Results. Patients with FM showed a hypofunctionality of the Gi protein system. In contrast, unaltered
Gi protein functionality was observed in patients with neuropathic pain, RA, and osteoarthritis. Patients
with FM also showed basal cAMP levels higher than controls. The reduced activity of Gi proteins
seems to be unrelated to a reduction of protein levels since only a slight reduction (about 20–30%) of
the Gi3α subunit was observed. 
Conclusions: Gi protein hypofunctionality is the first biochemical alteration observed in FM that could
be involved in the pathogenesis of this syndrome. In the complete absence of laboratory diagnostic
tests, the determination of an increase in cAMP basal levels in lymphocytes, together with the assess-
ment of a Gi protein hypofunctionality after adenylyl cyclase stimulation, may lead to the biochemical
identification of patients with FM. (J Rheumatol 2001;28:2298–304)
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the endogenous system of pain amplification and inhibition.
Pain indeed arises either when excitatory systems prevail or
when the inhibitory systems are defective. A condition of
hypofunctionality of the endogenous antinociceptive system
can, therefore, be hypothesized as the main cause of the symp-
toms experienced by patients with FM. However, from the
numerous studies conducted so far, no single receptor abnor-
mality has been observed. These considerations led us to look
beyond the receptor at the more universally distributed com-
ponents of cell signalling, G-proteins.
G-proteins are heterotrimeric molecules with α, ß and γ
subunits. The α subunits, which generally represent the func-
tional subunit of these proteins, can be classified into families,
depending on whether they are targets for cholera toxin (Gs),
pertussis toxin (Gi and Go) or neither (Gq and G12)18,19.
Activation of Gi proteins reduces cell excitability by inhibi-
tion of adenylyl cyclase activity and modulation of several K+
and Ca++ channels20-22. The involvement of Gi proteins in the
modulation of pain perception has long been known. The
administration of pertussis toxin, which selectively inactivates
Gi proteins23, produced hyperalgesia and allodynia in labora-
tory animals24-26, clearly indicating that a lack of functionality
of Gi proteins enhances the sensitivity to pain. Hypo-
functionality of Gi proteins also produces insensitivity to
analgesic treatments. It has been observed that pertussis toxin
prevents the enhancement of the pain threshold induced by
potent analgesic drugs such as opioids, antihistamines, and tri-
cyclic antidepressants25,27,28.
Taking into account these considerations, our purpose was
to determine whether an alteration in the Gi protein system
occurred in the FM syndrome. The Gi protein functionality
and expression were, therefore, investigated in peripheral
blood lymphocytes from patients with clinically well-defined
primary fibromyalgia.
MATERIALS AND METHODS
Subjects. Subjects were selected and classified into 3 groups: healthy volun-
teers (n = 17), patients with FM (n = 19) and patients with other types of pain
such as neuropathic pain (sciatica, carpal tunnel and other entrapment syn-
dromes, etc.), osteoarthritis, rheumatoid arthritis (n = 12). An informed con-
sent was obtained. Patients were instructed to cease all medications at least 6
days prior to testing. They all had undergone laboratory and physical exami-
nation to exclude the presence of other concomitant affections. Patients with
FM were classified, by attributing them an FM Score value, by following the
criteria of the American College of Rheumatology29. The VAS (visual analog
scale) value, which represents an arbitrary indication of the pain experienced,
and the FM Score value were evaluated for all subjects. All experiments were
performed blinded.
Isolation of human lymphocytes. Peripheral blood samples (15–20 ml) were
immediately anticoagulated with heparin sodium (500 UI heparin/10 ml
blood) and diluted 1:1 with saline solution. The lymphocytes were then iso-
lated using Ficoll-isopaque density-gradient centrifugation as described by
Böyum30. Mononuclear cells were counted.
Adenylyl cyclase activity assay in intact lymphocytes. Lymphocytes were first
permeabilized with the detergent digitonin (10 µg/ml) under such conditions
to maintain the biological functions intact31. The functionality of Gi proteins
was assessed by investigating their ability to inhibit stimulated adenylyl
cyclase activity in intact peripheral blood lymphocytes. Lymphocytes from
healthy subjects were preincubated with or without pertussis toxin (PTX) at a
concentration of 100 ng/ml at 37˚C for 90 min as described32, whereas lym-
phocytes from patients with FM and painful diseases were all preincubated
without PTX. After preincubation, for the determination of adenosine 3′,5′ —
cyclic monophosphate (cAMP) content, lymphocytes (1–2 × 106 intact
cells/assay) were incubated either with dimethyl sulphoxide (DMSO) or
forskolin 10-4 M to stimulate the cAMP formation32. To obtain the inhibition
curve of cAMP production the non-hydrolysable analogue of GTP Gpp(NH)p
(guanilyl 5′-imidophosphate) was added to the forskolin-containing samples
in concentrations ranging from 10 nM to 100 µM, in a final volume of 300 µl.
After a 15-minute incubation at 37°C, the cells were lysed and the sample
centrifuged according to Brodde, et al33. The cAMP content was determined
in 100 µl aliquot of the supernatant using an enzyme immunoassay kit
(Amersham). Protein concentration was determined by the bicinchoninic acid
protein assay kit (Sigma) with bovine serum albumin as standard. All assays
were performed in duplicate. The recovery of a known amount of cAMP (10
pmol) added to the incubation mixture after boiling was found to be 94.2 ±
7.8% (n = 6).
Lymphocyte lysates. Lymphocytes (5 × 106 cells) were lysed in 1 ml of 2 mM
Tris buffer pH 7.5 containing 100 mM EDTA, 0.1 mM benzamidine, 2.6 mM
leupeptin.
Western blot analysis. Lymphocyte Gi proteins were detected by Western
blotting. Aliquots of lymphocyte lysates (100 ml), or recombinant Gi2α and
Gi3α, used as reference proteins, were boiled for 5 min with 30 ml of sample
buffer (4% SDS, 20% glycerol, 10% 2-mercaptoethanol, 125 mMTris-HCl,
0.002% bromophenol blue at pH 8). The mixture (10 mg protein for each
sample) was separated by electrophoresis on sodium dodecyl sulfate-poly-
acrylamide gel according to Laemli34 using 10% acrylamide in the running
gel, then electroblotted to nitrocellulose membranes (Hybond-ECL 0.45 mm,
Amersham). Blots were pre-blocked for 90 min at room temperature with Tris
buffered saline (TBS) supplemented with 3% bovine serum albumin.
Following 2 washes (10 min each) with TBS [containing 0.5% Tween 20
(TTBS)] at room temperature, blots were incubated overnight at 4°C in TBS
supplemented with antisera suspension (1:2000 for anti Gi2α and 1:10000
working dilutions for Gi3α). Following removal of antisera, blots were washed
twice for 10 min with TTBS at room temperature. Thereafter each blot was
incubated with TTBS supplemented with a second monoclonal goat anti-rab-
bit peroxide conjugate antibody (1:5000 working dilution) for 1 h at room
temperature. Blots were then extensively washed (1 h) with several changes
of TTBS. Specific bands were detected using ECL system (Amersham)
according to the manufacturer’s instructions. Densitometric analysis of the
bands obtained was carried out using the Scion image program.
Statistical analysis. Results are given as the means ± SEM. An analysis of
variance (ANOVA), followed by Fisher’s protected least significant differ-
ence (PLSD) procedure for post-hoc comparison, was used to verify the sig-
nificance of differences between 2 means. Data were analysed with StatView
software for the Macintosh (1992).
RESULTS
Clinical characteristics of subjects. The characteristics of the
examined subjects are shown in Table 1. Patients with FM
were selected following the criteria established by the
American College of Rheumatology29 and attributed the cor-
responding Score Value. Patients with a Score Value of tender
points lower than 25 were not included in the study. As report-
ed in Table 1, patients with FM had Score Values 3 to 5 times
greater than patients with painful diseases, excluding the pres-
ence of a concomitant FM status in patients with neuropathic
pain, osteoarthritis, and rheumatoid arthritis. 
Patients with FM and painful diseases showed comparable
Galeotti, et al: Gi protein in FM 2299
Personal non-commercial use only.  The Journal of Rheumatology Copyright © 2001.  All rights reserved.
The Journal of Rheumatology 2001; 28:102300
VAS values indicating homogeneity of intensity of pain expe-
rienced (Table 1).
After selection and inclusion in the study, no subject was
then excluded.
Evaluation of Gi protein functionality. Adenylyl cyclase activ-
ity was stimulated by using the diterpene forskolin at a con-
centration of 10-4 M. The inhibition of cAMP production by
Gi proteins was then initiated by administration of Gpp(NH)p,
a non-hydrolyzable GTP analogue, in the concentration range
of 10-8–10-4 M. In lymphocytes from healthy subjects,
Gpp(NH)p produced a dose-dependent inhibition of forskolin-
stimulated adenylyl cyclase activity detectable by a reduction
of cAMP levels of about 40% (Figure 1a). In contrast,
Gpp(NH)p did not reduce cAMP levels after preincubation of
control lymphocytes with pertussis toxin (PTX) (Figure 1a). A
lack of inhibition of forskolin-stimulated adenylyl cyclase
activity, comparable to that produced by PTX preincubation
was observed in lymphocytes from patients with FM (Figure
1a). The distribution of single data points obtained from each
patient, in comparison with healthy subjects, is reported in
Figure 1b.
To exclude the possibility that the hypofunctionality of Gi
proteins observed was secondary to a condition of chronic
pain, we also investigated patients with painful syndromes
other than FM. Gpp(NH)p reduced cAMP levels in lympho-
cytes from patients with neuropathic pain, rheumatoid arthri-
tis, and osteoarthritis. In contrast to patients with FM, all these
patients showed an ability to inhibit adenylyl cyclase activity
similar to that of healthy subjects. The values reported in
Figure 2 were detected after the administration of Gpp(NH)p
10-5 M, a concentration corresponding to its maximum effect.
There was no statistically significant difference in cAMP val-
Table 1. Clinical variables in patients with FM and painful diseases.
Healthy FM Painful Diseases
Sex Age Score VAS Sex Age Score VAS Sex Age Score VAS
M 29 3 0 F 50 45 6.5 Neuropathic pain
M 32 2 0 F 70 60 5.2 F 60 12 8.0
M 43 4 0 F 65 53 6.0 M 75 2 9.3
F 58 2 0 F 74 48 9.2 F 61 16 5.4
F 49 10 0 F 80 60 8.5 F 72 5 9.3
F 36 6 0 F 68 32 8.1 F 55 7 7.3
F 25 1 0 F 59 40 7.8 Osteoarthritis
M 41 0 0 M 48 27 7.0 M 82 8 9.2
F 43 3 0 F 62 28 6.3 F 60 14 7.2
F 65 2 0 M 48 35 8.4 F 77 24 9.6
M 50 0 0 F 63 36 9.5 F 77 12 3.7
F 25 0 0 F 59 43 5.4 Rheumatoid arthritis
M 48 0 0 F 40 39 6.4 F 73 9 4.6
M 44 0 0 F 65 33 6.1 M 61 8 2.6
M 62 0 0 F 43 36 8.1 F 75 8 9.2
F 25 0 0 F 51 51 9.3
F 31 5 0 F 58 61 8.2
F 51 49 8.4
M 49 32 6.2
Score: Classification of FM by the criteria of the American College of Rheumatology28; VAS: visual analog scale.
Figure 1. Evaluation of Gi protein functionality in human lymphocytes. a.
Effect of increasing concentrations of Gpp(NH)p (10-8–10-4 M) on forskolin-
stimulated adenylyl cyclase activity in lymphocytes from healthy subjects
preincubated with or without pertussis toxin (PTX) and in lymphocytes of
patients with FM. Data are expressed as mean ± SEM ; *p < 0.05, **p < 0.01
in comparison with forskolin-stimulated lymphocytes. b. Distribution of sin-
gle data points obtained from each patient and healthy subject.
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ues obtained after stimulation with forskolin despite the fact
that in patients with osteoarthritis levels of cAMP were higher
than in all other groups (Figure 2).
Evaluation of cAMP basal levels. Under standard assay con-
ditions, basal cAMP levels in lymphocytes from healthy sub-
jects were 2.1 ± 0.3 pmol/106 lymphocytes (Figure 3a).
Patients with FM had basal levels of cAMP about 3 times
higher than the healthy group (Figure 3a). In contrast, the
basal cAMP levels of patients with neuropathic pain,
osteoarthritis, and rheumatoid arthritis were not statistically
different from controls (Figure 3a). Moreover, the percentage
of enhancement of cAMP production from basal levels after
stimulation of adenylyl cyclase activity with forskolin 10-4 M
was similar in all groups (80–90%). In contrast, it was signif-
icantly lower in patients with FM (Figure 3b).
Quantitative determination of Giα levels. The expression of
Giα and of the subtypes Gi2α and Gi3α proteins was investigat-
ed. As illustrated in Figure 4, levels of Giα, Gi2α and Gi3α
quantified by optical densitometry were similar in lympho-
cytes from both healthy subjects and patients with FM. Gi3α
levels showed a slight reduction (about 25%), which did not
reach statistical significance (Figure 4).
DISCUSSION
Lymphocytes from patients with FM showed a reduced capa-
bility to inhibit forskolin-stimulated adenylyl cyclase activity
as well as higher cAMP basal levels, clearly indicating a
hypofunctionality of Gi proteins in FM. The impaired capa-
bility to inhibit forskolin-stimulated adenylyl cyclase activity
was similar to that produced by preincubation of lymphocytes
from healthy subjects with pertussis toxin at a concentration
consistent with a complete ADP-ribosilation of Gi proteins35.
These considerations further support the hypothesis of a selec-
tive hypofunctionality of Gi proteins in this syndrome.
In addition, lymphocytes from patients with FM showed
higher basal levels of cAMP, indicating an impaired equilibri-
um between the inhibitory and stimulatory system of adenylyl
cyclase, mediated, respectively, by Gi and Gs proteins. These
data further confirm the hypothesis of a hypofunctionality of
Gi proteins, which is detectable both under basal conditions
and after stimulation of the adenylyl cyclase system. An alter-
ation at the level of adenylyl cyclase can be excluded since the
direct stimulation of the enzyme by forskolin did not reveal
any difference in the cAMP levels produced between patients
and healthy subjects. However, it should be noted that sub-
jects with osteoarthritis showed both basal and stimulated
cAMP levels tendentially higher than all other subjects. This
effect seems not to be related to an altered functionality of the
Gi protein system since the percentage of increase of cAMP
level after forskolin stimulation, as well as the amount of
Figure 2. Hypofunctionality of Gi proteins in patients with FM. Effect of
Gpp(NH)p (10-5 M) on forskolin-stimulated adenylyl cyclase activity in lym-
phocytes from patients with FM (F), neuropathic pain (NP), osteoarthritis
(O), or rheumatoid arthritis (RA) in comparison with healthy (H) subjects.
Data are expressed as mean ± SEM; *p < 0.05 in comparison with forskolin-
stimulated lymphocytes. : forskolin 10-4 M; : forskolin 10-4 M +
Gpp(NH)p 10-5 M.
Figure 3. Evaluation of basal cAMP levels in patients with FM. The deter-
mination of basal cAMP levels (a) and increase of cAMP levels after stimu-
lation with forskolin 10-4 M (b) in patients with FM (F), neuropathic pain
(NP), osteoarthritis (O), or rheumatoid arthritis (RA) in comparison with
healthy subjects. Data are expressed as mean ± SEM; *p < 0.05 in compari-
son with lymphocytes from healthy subjects.
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cAMP reduction after Gpp(NH)p administration, is compara-
ble to those observed in healthy subjects. The presence of
higher cAMP levels might be explained by taking into account
that patients with osteoarthritis were slightly older. Indeed, in
our experimental conditions, even though no statistically sig-
nificant correlation between cAMP levels and age was detect-
ed, there was a tendency to an increase in cAMP production
with the age (data not shown). However, other mechanisms
cannot be excluded.
A reduced functionality of the endogenous antinociceptive
system mediated by Gi proteins might be responsible for the
widespread pain and allodynia typical of the FM syndrome. It
is well known, indeed, that Gi protein activation inhibits the
production of cyclic AMP, opens some potassium channels
and closes some calcium channels, thus reducing cell
excitability22. A deficiency of the Gi protein-mediated
inhibitory system, therefore, produces cell hyperexcitability,
which can lead to a hypersensitivity to pain. It has been
reported that in laboratory animals, Gi protein inactivation
produces hyperalgesia and allodynia24-26. Our results are also
in agreement with the most recent hypothesis on the patho-
genesis of FM, which considers an altered central mechanism
of nociception as the biological basis of this syndrome13,14.
Furthermore, the Gi protein hypofunctionality we have
observed may well represent the biological mechanism
responsible for the hypersensitivity to pain in FM.
To evaluate the functionality of Gi proteins, we detected
the ability of the non-hydrolysable GTP analogue Gpp(NH)p
to inhibit adenylyl cyclase activity. This enzymatic activity
was previously amplified by forskolin, a diterpene that selec-
tively activates adenylyl cyclase36, at a concentration of 10-4
M, which is reported to be the most effective one in human
lymphocytes32.
Considering the multiplicity of GTP-binding proteins pre-
sent in lymphocytes37, it may seem difficult to detect a defect
in a particular G-protein subtype with the use of a GTP ana-
logue. However, not only a preferential affinity of Gpp(NH)p
towards Gi proteins in the range of concentrations used has
been evidenced38,39, but also a widely different expression of
each type of G protein is documented, indicating that Gi are
commonly 10 times more abundant than Gs40. Therefore,
Gpp(NH)p is a suitable tool for a selective investigation into
Gi protein functionality.
Since the hypofunctionality of Gi proteins could underlie a
reduction of the protein expression, we determined Gi protein
levels by Western blot analysis. A slight reduction in Gi sub-
unit levels was observed in lymphocytes from patients with
FM. Considering that several Gi protein subtypes belong to
the Gi family, in order to ascertain whether this reduction was
related to a single subtype, we used specific antibody against
Gi2α and Gi3α. Gi2 is the Gi protein subtype mainly involved
in the inhibitory regulation of adenylyl cyclase activity in
vivo41 and it plays an important role in the modulation of pain
perception. The administration of selective antibodies against
Gi2α as well as the inhibition of its expression by the use of
specific antisense oligonucleotides prevented the analgesia
induced by agonists of µ-opioid receptors42,43. Similarly to
Gi2, Gi3 has been reported to be also involved in pain pro-
cessing since antibodies against Gi3α prevented δ-opioid anal-
gesia44. Western blot analysis evidenced a slightly more
marked reduction in Gi3α levels rather than in Gi2α. However,
considering that a difference in Giα levels between healthy
and fibromyalgic subjects greater than 20–30% was never
observed, we cannot establish from these data whether a
reduction in protein levels contributes to the Gi protein hypo-
functionality.
Gi proteins are coupled to many receptor types and sub-
types. It is also well known that Gi protein levels can be
down-regulated at several levels, such as turnover, transcrip-
tion etc., by hormones and neurotransmitters. Considering that
all subjects included in this study were drug-free for at least
one week, we can assume that the observed Gi protein hypo-
functionality represents an individual’s predisposition to FM
rather than a down-regulation produced by the pharmacologi-
cal treatment.
It can also be excluded that the observed hypofunctionali-
ty of Gi proteins might be an adaptive response to a condition
Figure 4. Evaluation of Gi protein levels in lymphocytes of patients with FM.
Data are reported as a percentage of Gi levels in comparison with healthy sub-
jects. Inset: bands obtained by Western blot analysis.
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of chronic pain. Patients with painful diseases such as neuro-
pathic pain, osteoarthritis, or rheumatoid arthritis, who expe-
rienced pain sensations comparable to FM, as indicated by the
VAS values, showed an unaltered Gi protein functionality. 
The investigation into the Gi protein functionality was con-
ducted in lymphocytes from peripheral blood taking into
account that Gi proteins have an ubiquitous distribution19 and
that blood samples can be is easily obtained from patients in a
painless manner. Lymphocytes represent an appropriate tool
to detect Gi protein functionality since they have cell surface
recognition sites for pertussis toxin, the selective inactivator
of Gi. These recognition sites are lacking in other blood cell
types such as erythrocytes45. Indeed, lymphocytes have been
widely used to investigate the pathogenesis of various human
diseases at a biochemical and molecular level46-50.
Gi protein hypofunctionality is the first biochemical alter-
ation observed in FM, and may well be involved in the patho-
genesis of this syndrome. Furthermore, in the complete
absence of laboratory diagnostic tests, the determination of an
increase in cAMP basal levels in lymphocytes, together with
the assessment of a Gi protein hypofunctionality after adeny-
lyl cyclase stimulation, might lead to the biochemical identi-
fication of patients with FM.
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